A longitudinal study of anti-SARS-CoV-2 antibody seroprevalence in a random sample of the general population in Hiroshima in 2020.

Aya SugiyamaFumie OkadaKanon AbeHirohito ImadaSerge OuobaBunthen EMd Razeen Ashraf HussainMasayuki OhisaKo KoShintaro NagashimaTomoyuki AkitaShinichi YamazakiMichiya YokozakiEisaku KishitaJunko Tanaka

Published in: Environmental health and preventive medicine (2022)

The seroprevalence of anti-SARS-CoV-2 antibodies in Hiroshima increased tenfold in a half year. The difference between seroprevalence and the prevalence of confirmed COVID-19 cases in Hiroshima was smaller than that in other prefectures, suggesting that asymptomatic patients were more actively detected in Hiroshima.

Keyphrases

sars cov
respiratory syndrome coronavirus
end stage renal disease
ejection fraction
newly diagnosed
coronavirus disease
chronic kidney disease
risk factors